Is MSAFP Still a Useful Test for Detecting Open Neural Tube Defects and Ventral Wall Defects in the Era of First-Trimester and Early Second-Trimester Fetal Anatomical Ultrasounds?

Introduction: To evaluate whether maternal serum α-fetoprotein (MSAFP) improves the detection rate for open neural tube defects (ONTDs) and ventral wall defects (VWD) in patients undergoing first-trimester and early second-trimester fetal anatomical survey. Material and Methods: A cohort of women undergoing screening between 2005 and 2012 was identified. All patients were offered an ultrasound at between 11 weeks and 13 weeks and 6 days of gestational age for nuchal translucency/fetal anatomy followed by an early second-trimester ultrasound at between 15 weeks and 17 weeks and 6 days of gestational age for fetal anatomy and MSAFP screening. All cases of ONTD and VWD were identified via query of billing and reporting software. Sensitivity and specificity for detection of ONTD/VWD were calculated, and groups were compared using the Fisher exact test, with p < 0.05 as significance. Results: A total of 23,790 women met the criteria for inclusion. Overall, 15 cases of ONTD and 17 cases of VWD were identified; 100% of cases were diagnosed by ultrasound prior to 18 weeks' gestation; none were diagnosed via MSAFP screening (p < 0.001). First-trimester and early second-trimester ultrasound had 100% sensitivity and 100% specificity for diagnosing ONTD/VWD. Discussion: Ultrasound for fetal anatomy during the first and early second trimester detected 100% of ONTD/VWD in our population. MSAFP is not useful as a screening tool for ONTD and VWD in the setting of this ultrasound screening protocol.

[1]  K. Kagan,et al.  ISUOG Practice Guidelines: performance of first‐trimester fetal ultrasound scan , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[2]  F. Binokay,et al.  Prenatal Determination of the Upper Lesion Level of Spina Bifida with Three-Dimensional Ultrasound , 2012, Fetal Diagnosis and Therapy.

[3]  K. Nicolaides,et al.  First-Trimester Screening for Neural Tube Defects Using Alpha-Fetoprotein , 2012, Fetal Diagnosis and Therapy.

[4]  J. Martin,et al.  Births: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[5]  K. Nicolaides,et al.  Challenges in the diagnosis of fetal non‐chromosomal abnormalities at 11–13 weeks , 2011, Prenatal diagnosis.

[6]  Zhi-Ping Wang,et al.  The effectiveness of prenatal serum biomarker screening for neural tube defects in second trimester pregnant women: a meta‐analysis , 2009, Prenatal diagnosis.

[7]  I. Timor-Tritsch,et al.  Performing a Fetal Anatomy Scan at the Time of First-Trimester Screening , 2009, Obstetrics and gynecology.

[8]  P. Antsaklis,et al.  Assessment of fetal anatomy at the 11–14‐week ultrasound examination , 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[9]  AIUM Practice Guideline for the Performance of an Antepartum Obstetric Ultrasound Examination , 2003, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[10]  William Grobman.  ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 44, July 2003. (Replaces Committee Opinion Number 252, March 2001). , 2003, Obstetrics and gynecology.

[11]  M. Zugaib,et al.  Detection of fetal structural abnormalities at the 11–14 week ultrasound scan , 2002, Prenatal diagnosis.

[12]  Gynecologists.  ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 32, November 2001 (replaces Technical Bulletin Number 181, June 1993, and Committee Opinion Number 241, September 2000). Thyroid disease in pregnancy. , 2001, Obstetrics and gynecology.

[13]  D. Gray,et al.  Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. , 1999, Obstetrics and gynecology.

[14]  D. Keret,et al.  Transvaginal sonographic detection of skeletal anomalies in the first and early second trimesters , 1993, Prenatal diagnosis.

[15]  M. Whittle,et al.  Ultrasound Detection of Neural Tube Defects in Patients with Elevated Maternal Serum Alpha-Fetoprotein , 1991, Obstetrics and gynecology.

[16]  I. Timor-Tritsch,et al.  Transvaginal ultrasonographic definition of the central nervous system in the first and early second trimesters. , 1991, American journal of obstetrics and gynecology.

[17]  J. Haddow,et al.  Second‐Trimester Maternal Serum Alpha‐Fetoprotein Levels in Pregnancies Associated With Gastroschisis and Omphalocele , 1988, Obstetrics and gynecology.

[18]  A. Milunsky.  Prenatal detection of neural tube defects. VI. Experience with 20,000 pregnancies. , 1980, JAMA.

[19]  J. Brooks-Gunn.  MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY: , 1978 .

[20]  N J Wald,et al.  MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY Report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects , 1977, The Lancet.

[21]  R. Weiss,et al.  Prenatal detection of neural tube defects. Comparison between alpha-fetoprotein and beta-trace protein assays. , 1975, American journal of obstetrics and gynecology.